- By insider
Nuvectra Corp (NVTR) files its latest 10-K with SEC for the fiscal year ended on December 31, 2018. Nuvectra Corp is a medical device company in the United States. It manufactures devices to address chronic neurological disorders. The company has two reportable segments namely Nuvectra and NeuroNexus. Nuvectra Corp has a market cap of $228.030 million; its shares were traded at around $12.89 with and P/S ratio of 3.35.
-
Warning! GuruFocus has detected 4 Warning Signs with CRM. Click here to check it out.
-
The intrinsic value of NVTR
For the last quarter Nuvectra Corp reported a revenue of $14.2 million, compared with the revenue of $7.62 million during the same period a year ago. For the latest fiscal year the company reported a revenue of $48.8 million, an increase of 53.4% from last year.
The reported loss per diluted share was $3.25 for the year, compared with the loss per share of $0 in the previous year. The Nuvectra Corp had an operating margin of -88.44%, compared with the operating margin of -131.96% a year before. The 10-year historical median operating margin of Nuvectra Corp is -377.38%. The profitability rank of the company is 4 (out of 10).
At the end of the fiscal year, Nuvectra Corp has the cash and cash equivalents of $99.2 million, compared with $28.2 million in the previous year. The long term debt was $44.1 million, compared with $25.9 million in the previous year. Nuvectra Corp has a financial strength rank of 6 (out of 10).
At the current stock price of $12.89, Nuvectra Corp is traded at 36.2% discount to its historical median P/S valuation band of $20.21. The P/S ratio of the stock is 3.35, while the historical median P/S ratio is 5.27. The stock gained 19.24% during the past 12 months.
For the complete 20-year historical financial data of NVTR, click here.
This article first appeared on GuruFocus.
-
Warning! GuruFocus has detected 4 Warning Signs with CRM. Click here to check it out.
-
The intrinsic value of NVTR